The novel DNA binding mechanism of ridinilazole, a precision Clostridiodes difficile antibiotic.
Clive Mason(e-Therapeutics (United Kingdom)), David J. Powell(Summit (United Kingdom)), Nabeetha Nagalingam, Kathleen Gajewski(University of Houston), Chenlin Hu(University of Houston), Stephen Moss(Domainex (United Kingdom)), Tim Avis(Wellcome Sanger Institute), Kevin W. Garey(University of Houston), M. Jahangir Alam(University of Houston), Khurshida Begum(University of Houston), Keith R. Fox(University of Southampton), Chris Coward(Summit (United Kingdom)), Esther Duperchy(Johns Hopkins Hospital), Stefanie Reich(Domainex (United Kingdom)), Manikhandan Mudaliar(University of Glasgow)
Cited by 2
Related Papers
Patterns of somatic mutation in human cancer genomes
|Nature|2007|3.1k
Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)
|Clinical Infectious Diseases|2017|2.7k
Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)
|Clinical Infectious Diseases|2018|1.2k
Somatic Mutations of the Protein Kinase Gene Family in Human Lung Cancer
|Cancer Research|2005|466